SARD279 , CAS No.1489236-55-6

CAS: 1489236-55-6 Cat. No.: S1450365 Formula: C₃₃H₄₁F₃N₄O₅S Peso molecolare: 662.76

Storage

Store at 2-8°C

Shipped In

Wet ice

Panoramica

SARD279 is a potent and selective Androgen Receptor degrader with DC 50 value of 1099 nM. SARD279 can be used in prostate cancer research.(Structure Note: Pink: target protein ligand ;Blue,: Hyt ;Black: linker )

Specifications

Condizioni di conservazione di stoccaggio

Store at 2-8°C

Spedito in

Wet ice

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Nomi e identificatori

• Peso molecolare: 662.76

Application Protocols

Item-specific tested applications, dilutions, and controls: Not specified for this item.

General protocols for small-molecule screening compounds (not specifications):

• Stock solution: Prepare a 10–20 mM DMSO stock in an amber vial. Record exact concentration by weight-in or by UV if an extinction coefficient is available.
• Plate handling: Use low-bind plates/tips. Pre-dilute in DMSO or DMSO/buffer to create intermediate concentrations, then transfer to assay plates to achieve the final desired range while keeping DMSO constant (e.g., 0.1–0.5% v/v).
• Serial dilution: Use half-log or 3-fold serial dilutions to span intended potency ranges. Include vehicle-only and positive control wells.
• Readouts: Choose orthogonal readouts (e.g., binding vs. functional) to confirm activity. For degradation studies, include proteasome inhibitor rescue controls and time-course sampling.
• Data quality: Track Z′-factor, signal-to-background, and precipitation flags. Confirm hits with independently prepared stocks or fresh vials.

Documentation:

• Retain CoA, lot number, preparation log, and storage history for data traceability.

Biological Roles

Item-specific biological data for this SKU: Not specified for this item; refer to CoA/Spec Sheet and primary literature as needed.

General/literature context (not item-specific claims; for research planning only):

• The SARD designation is used in the literature for selective androgen receptor degraders/antagonists. Such chemotypes are investigated as chemical biology tools to modulate the androgen receptor (AR), a nuclear hormone receptor regulating androgen-responsive gene transcription. In cell-based studies, AR engagement can be evaluated by reporter assays, qPCR of AR target genes, or protein level monitoring by Western blot.
• Mechanistic themes: Ligand binding to AR’s ligand-binding domain can either antagonize transcriptional activation or, for degrader designs, promote receptor destabilization and proteasomal turnover. Distinguishing antagonism from degradation requires orthogonal assays (e.g., proteasome inhibition rescue, cycloheximide chase).
• ADME considerations in vitro: Lipophilic ligands may bind serum proteins and plasticware; adsorption can cause apparent potency shifts. Employ low-bind consumables and consistent serum conditions.

Compliance reminder:

• For research use only. No clinical, diagnostic, or therapeutic claims are made or implied for this SKU.

Buffer Applications

This SKU is a small-molecule library compound and is not a buffering agent. Therefore, conventional buffer system guidance (pKa-based formulations, buffering ranges) is not typically applicable.

Practical notes for assay buffers (general):

• Vehicle control: Match DMSO or other co-solvent content in all wells or samples (e.g., 0.1–0.5% v/v) to avoid solvent-driven effects.
• Surfactants: If precipitation or compound adsorption is observed, very low levels of non-ionic surfactant (e.g., 0.01–0.05% Tween-20 or Pluronic F-68) can improve tolerance—validate against your assay readout.
• Protein content: Serum or BSA can alter free concentration through binding; keep protein content constant across conditions or measure free fraction when feasible.

Green Alternatives

Because SARD279 is a discrete small molecule used primarily as a research probe/library member rather than a bulk solvent or reagent, “green alternatives” are most relevant to handling solvents and processes around its use, not to replacing the compound itself.

Greener handling strategies (general guidance):

• Stock solutions: Prefer aqueous-compatible solvents (e.g., DMSO) at minimal final assay percentages (≤0.1–0.5%) to reduce organic solvent loads.
• Solvent reduction: For purification or reconstitution, use microscale operations (96/384-well formats) to minimize solvent volumes. Where possible, substitute high-toxicity solvents (e.g., DMF, NMP) with ethanol, isopropanol, or PEG-400/water co-solvent systems, validating assay compatibility.
• Waste management: Segregate halogenated from non-halogenated organic waste; capture DMSO-containing aqueous streams separately if required by local regulations.

Illustrative comparison (general; not item-specific):

• DMSO vs. DMF/NMP: DMSO offers lower acute toxicity and better biodegradability profile; choose DMSO when solubility permits.
• Ethanol/IPA as co-solvents: Renewable feedstock options exist; their higher volatility may reduce energy for solvent removal but can affect assay systems—validate carefully.

Note: No greener “alternative compound” can be recommended without altering the research objective; if your goal is AR pathway interrogation, consider whether less lipophilic analogs or validated reference ligands meet your EHS constraints.

Pharmaceutical Uses

This product is supplied strictly for research use only and is not intended for human or veterinary use, clinical trials, or diagnostic applications.

General formulation context (not item-specific and not a recommendation for clinical use):

• Small-molecule research probes are sometimes formulated for in vivo exploratory studies in preclinical species using vehicles such as DMSO/PEG-400/saline, Captisol, or aqueous micellar systems. Any such use requires institutionally approved protocols and compound-specific stability/tox data, which are not provided here.
• No pharmacopoeial monograph or excipient status is indicated for this item. There is no grade designation (USP/EP) in the Product Data.

Conclusion for this SKU:

• No pharmaceutical or excipient uses are specified. For discovery-stage experiments, limit to in vitro or ex vivo studies unless your institution’s compliance and safety review supports additional work with independently verified data.

Physical Properties

Item-specific properties (from Product Data):

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Literature/general expectations for small-molecule screening compounds (not specifications):

• Physical state: Many library compounds are crystalline or amorphous solids at ambient temperature.
• Solubility: Frequently soluble in polar aprotic solvents (DMSO, DMF, NMP) and variably soluble in aqueous buffers depending on ionizable groups. For assay use, 10–20 mM DMSO stocks are commonly prepared and diluted into buffers immediately before use to minimize precipitation.
• Partitioning: Lipophilic chemotypes often exhibit higher logP/logD and limited aqueous solubility; verify with experimental or predicted data before designing concentrations above 10–30 µM in aqueous media.
• UV–Vis: Small molecules often have UV absorption in 200–350 nm; measure actual spectrum to avoid interference in absorbance-based assays.

Not provided for this item (consult CoA/SDS or determine experimentally):

• Melting point, boiling point, density, refractive index, pKa, logP/logD, water content, residual solvents, and UV cutoff are Not specified for this item; refer to CoA/Spec Sheet.

Recommendations:

• Determine solubility and stability in intended assay matrix by small-scale serial dilution and visual inspection/LC–MS. Filter (0.2 µm PTFE) if particulate forms, and monitor for time-dependent precipitation.

Quality and Grades

Item-specific quality information (from Product Data):

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

How to interpret common grades (general guidance; not specific to this item):

• Screening/compound library grade: Typically provided with identity confirmation (e.g., LC–MS and/or 1H NMR) and purity sufficient for discovery assays. UV absorbance profiles and trace metals are usually not controlled to chromatographic solvent standards.

• 95% purity (if stated on CoA): Generally suitable for biochemical and cellular assays; impurities can confound SAR at low effect sizes—verify by orthogonal analytics when possible.

• HPLC assay vs. qNMR: HPLC peak area % reflects chromatographic purity; qNMR provides mass fraction purity. Use the method that best matches your application.

Recommendations for this SKU:

• Request and review the CoA for identity (LC–MS, NMR), purity, and water/residual solvent content if relevant to your assays.
• If your work is sensitivity-limited (e.g., biophysical binding or MS-based quantification), perform in-house verification (HPLC/UPLC, qNMR) on receipt.

Stabilizers/inhibitors:

• Not specified for this item; refer to CoA/Spec Sheet. If stabilizers are present, understand their potential to interfere with downstream assays.

Reaction and Applications

This product is sold as a research small molecule/compound library member rather than as a synthetic reagent, so it is not typically deployed as a stoichiometric reactant in conventional organic synthesis.

Research applications (general/literature context; not item-specific claims):

• The SARD naming convention is associated in the literature with selective androgen receptor degraders/antagonists used as chemical probes in target validation and mechanism studies in the ubiquitin–proteasome context. Compounds of this class are commonly evaluated in binding/functional assays, degradation assays (e.g., Western blot time-courses), and SAR campaigns.

Practical guidance for use in discovery workflows (general):

• Assay preparation: Prepare concentrated DMSO stocks, verify solubility upon dilution, and include vehicle controls matched for DMSO content.
• Analytical support: Use LC–MS to track compound integrity during storage and assay setup; monitor for hydrolysis/oxidation if relevant functional groups are suspected.
• Controls: Include negative controls and, where applicable, reference AR ligands/degraders to contextualize activity.

If you intend to use this item as a synthetic intermediate:

• No synthetic reactivity, functional groups, or protecting-group compatibilities are specified for this SKU. Obtain structural information from the CoA and assess feasibility before planning transformations.

Reaction Conditions

This SKU is not supplied as a reagent for chemical synthesis, and no reaction condition guidance is specified in the Product Data.

General guidance for handling during assay preparation (not item-specific specifications):

• Stock preparation: Dissolve the compound in dry, anhydrous DMSO to prepare a concentrated stock (e.g., 10–20 mM). Vortex and, if needed, sonicate briefly. Filter through 0.2 µm PTFE if particulates persist.
• Dilution: Add stock to assay buffer as the final step to minimize precipitation; maintain a consistent final co-solvent percentage across samples.
• Stability checks: Assess solution stability by LC–MS after storage at 2–8°C and after freeze–thaw cycles. If degradation is observed, prepare fresh stocks more frequently and limit exposure to ambient light.

If planning chemical transformations:

• No item-specific functional groups or reactivity data are available; obtain the structure and consult standard reaction conditions appropriate to the identified handles (e.g., Suzuki for aryl boronates/halides, amide couplings with carbodiimides or uronium reagents).

Safety and Handling

Authoritative safety data must be taken from the item-specific SDS.

Item-specific hazard information (from Product Data):

• Signal Word: Not specified for this item; refer to SDS.
• H-Statements: Not specified for this item; refer to SDS.
• GHS Classification: Not specified for this item; refer to SDS.
• Pictograms: Not specified for this item; refer to SDS.

General laboratory precautions for small-molecule research compounds (not item-specific):

• PPE: Use lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Handle powders/solutions in a fume hood to avoid inhalation or aerosol exposure.
• Avoid contact with skin and eyes; prevent ingestion and inhalation of dust or vapors. Wash thoroughly after handling.
• Storage incompatibilities: Keep away from strong oxidizers and strong acids/bases unless compatibility is known. Avoid prolonged exposure to light and moisture for stability.
• First aid (general): If on skin/eyes, rinse with water for ≥15 minutes; remove contaminated clothing. If inhaled, move to fresh air. If ingested, rinse mouth. Seek medical attention as per SDS guidance.
• Spill response: For small spills, absorb with inert material (e.g., vermiculite), collect in suitable container, and decontaminate area. Dispose of waste via approved chemical waste streams.

Research use note (from Product Data):

• For research use only. Not for human or veterinary use, diagnostics, or clinical applications.

Solvent Selection

Item-specific solvent and solubility data: Not specified for this item; refer to CoA/Spec Sheet.

General guidance for small-molecule library compounds (not specifications):

• Primary stock solvent: DMSO is the default for discovery compounds due to broad solvency and biological compatibility at ≤0.1–0.5% v/v in assays.
• Alternative solvents: DMF, NMP, ethanol, or isopropanol can be used if DMSO solubility is inadequate; co-solvent strategies (e.g., DMSO + aqueous buffer + surfactant like 0.01–0.05% Tween-20) may help.
• Aqueous media: Direct dissolution into water or buffers can be limited; consider pH adjustment if the compound bears ionizable groups (determine pKa experimentally or via prediction first).
• Miscibility and compatibility:
  • DMSO: Miscible with water and many organics; may interact with certain enzymes/receptors—keep final assay DMSO ≤1% when possible.
  • Ethanol/IPA: Miscible with water; higher volatility can aid solvent removal but may affect cells/binding systems above ~0.5–1%.

Decision tips:

• Start with a 10–20 mM DMSO stock, evaluate clarity after serial dilution into assay buffer. If precipitation occurs, reduce final concentration or use a modest co-solvent fraction.
• For spectroscopic assays, verify that the chosen solvent does not introduce interfering background or cause compound aggregation (check by light scattering and control wells).

Storage and Reconstitution

Item-specific conditions (from Product Data):

• Storage Conditions: Store at 2–8°C.
• Shipped In: Wet ice.

General guidance (not item-specific specifications):

• Container: Store solid or solution in airtight, chemically compatible vials (e.g., amber glass) with desiccant if moisture-sensitive. Protect from light until stability is confirmed.
• Stock solutions: Prepare concentrated DMSO stocks (e.g., 10–20 mM) in anhydrous solvent. Aliquot into single-use volumes to avoid repeated freeze–thaw.
• Freeze–thaw: Minimize cycles. If freezing solutions, consider −20°C to −80°C depending on stability; record the number of cycles and discard aliquots showing precipitation or degradation by LC–MS/HPLC.
• Reconstitution: Bring vial to room temperature before opening to avoid moisture condensation. For solids, weigh rapidly and dissolve with gentle vortexing/sonication. For solutions, inspect for particulates/crystals and clarify via 0.2 µm PTFE filtration if needed.
• Stability monitoring: Periodically check by LC–MS/HPLC for degradation and by visual inspection for precipitation. Adjust storage (temperature, light protection, headspace) based on observed stability.

Note:

• If the CoA provides specific solvent, concentration, or stability instructions, those supersede the general guidance above.

Structure and Identity

Item-specific identifiers (from Product Data):

• SKU: S1450365
• Product Name: SARD279
• CAS: 1489236-55-6
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structure description:

• Item-specific structural features: Not specified for this item; refer to CoA/Spec Sheet.

General/literature context (for orientation only; not item-specific specifications):

• The name “SARD279” appears in the chemical biology literature as a small-molecule androgen receptor (AR) degrader/antagonist scaffold (Selective Androgen Receptor Degrader, SARD). Exact atom connectivity, stereochemistry, and substitution pattern must be verified against the certificate of analysis for this catalog item before use in regulated or quantitative studies.

Practical note:

• If structural confirmation is required for your workflow (e.g., NMR or LC–MS qualification), request the CoA/Spec Sheet or perform independent analytical verification (1H/13C NMR, HRMS, HPLC).

Synthetic Utility

As offered, SARD279 is a target small molecule intended for screening/biological evaluation rather than as a general synthetic reagent or building block.

Item-specific reactive functionality: Not specified for this item; refer to CoA/Spec Sheet.

General considerations if derivatization is contemplated (not item-specific):

• Functional handle mapping: Identify heteroatoms, aryl halides, or activated positions that could enable late-stage diversification (e.g., cross-coupling, amide coupling, SNAr). Confirm by full structural characterization.
• Protecting-group compatibility: If multiple nucleophilic/acidic sites are present, plan orthogonal protection; verify stability toward bases/acids and oxidants used in coupling or modification steps.
• Analytical support: After modification, confirm identity and purity via HRMS, 1H/13C NMR, and HPLC. For bioactive chemotypes, maintain stereochemical integrity; monitor for atropisomerism or epimerization where relevant.

If you require a functionalized analog for probe development (e.g., biotinylated/fluorophore-tagged):

• Consider introducing linkers at solvent-exposed regions indicated by SAR or docking data, and assess retention of activity with minimal perturbation.

Target Specificity

Item-specific biological target data from Product Data: Not specified for this item.

General/literature context (not item-specific claims):

• Compounds labeled as SARD in the literature are commonly explored for activity at the androgen receptor (AR). However, target engagement, selectivity over related nuclear receptors, and off-target profiles are highly structure- and assay-dependent and must be empirically determined for the exact material in hand.

Recommendations:

• Establish target specificity using a panel of orthogonal assays: ligand-binding displacement, transcriptional reporter assays, proteomics-based degradation profiling (if applicable), and counterscreens against related receptors (GR, PR, MR).
• Include cytotoxicity profiling and DMSO vehicle controls to distinguish target-mediated effects from non-specific perturbation.